[1]
|
Wen, P.Y., Weller, M., Lee, E.Q., Alexander, B.M., Barnholtz-Sloan, J.S., et al. (2020) Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions. Neuro-Oncology, 22, 1073-1113. https://doi.org/10.1093/neuonc/noaa106
|
[2]
|
Louis, D.N., Ohgaki, H., Wiestler, O.D., Cavenee, W.K., Burger, P.C., et al. (2007) The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathologica, 114, 97-109. https://doi.org/10.1007/s00401-007-0243-4
|
[3]
|
Weller, M. and Van Den Bent, M. (2021) EANO Guidelines on the Diagnosis and Treatment of Diffuse Gliomas of Adulthood. Nature Reviews Clinical Oncology, 18, 170-186. https://doi.org/10.1038/s41571-020-00447-z
|
[4]
|
Stupp, R., Mason, W.P., Van Den Bent, M.J., Weller, M., Fisher, B., et al. (2005) Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. The New England Journal of Medicine, 352, 987-996. https://doi.org/10.1056/NEJMoa043330
|
[5]
|
Weller, M., Cloughesy, T., Perry, J.R. and Wick, W. (2013) Standards of Care for Treatment of Recurrent Glioblastoma—Are We There Yet? Neuro-Oncology, 15, 4-27. https://doi.org/10.1093/neuonc/nos273
|
[6]
|
Stupp, R., Taillibert, S., Kanner, A., Read, W., Steinberg, D., et al. (2017) Effect of Tumor-Treating Fields plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients with Glioblastoma: A Randomized Clinical Trial. JAMA, 318, 2306-2316. https://doi.org/10.1001/jama.2017.18718
|
[7]
|
Poon, M.T.C., Sudlow, C.L.M., Figueroa, J.D. and Brennan, P.M. (2020) Longer-Term (≥ 2 Years) Survival in Patients with Glioblastoma in Population-Based Studies Pre-and Post-2005: A Systematic Review and Meta-Analysis. Scientific Reports, 10, Article No. 11622. https://doi.org/10.1038/s41598-020-68011-4
|
[8]
|
Luo, C., Song, K., Wu, S., Hameed, N.U.F., Kudulaiti, N., et al. (2021) The Prognosis of Glioblastoma: A Large, Multifactorial Study. British Journal of Neurosurgery, 35, 555-561. https://doi.org/10.1080/02688697.2021.1907306
|
[9]
|
Omuro, A. and DeAngelis, L.M. (2013) Glioblastoma and Other Malignant Gliomas: A Clinical Review. JAMA, 310, 1842-1850. https://doi.org/10.1001/jama.2013.280319
|
[10]
|
Nuño, M., Birch, K., Mukherjee, D., Sarmiento, J.M., Black, K.L., et al. (2013) Survival and Prognostic Factors of Anaplastic Gliomas. Neurosurgery, 73, 458-465. https://doi.org/10.1227/01.neu.0000431477.02408.5e
|
[11]
|
Cohen, A.L. and Colman, H. (2015) Glioma Biology and Molecular Markers. Cancer Treatment Research, 163, 15-30. https://doi.org/10.1007/978-3-319-12048-5_2
|
[12]
|
Brat, D.J., Verhaak, R.G., Aldape, K.D., Yung, W.K., Salama, S.R., et al. (2015) Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. The New England Journal of Medicine, 372, 2481-2498. https://doi.org/10.1056/NEJMoa1402121
|
[13]
|
Hartmann, C., Meyer, J., Balss, J., Capper, D., Mueller, W., et al. (2009) Type and Frequency of IDH1 and IDH2 Mutations Are Related to Astrocytic and Oligodendroglial Differentiation and Age: A Study of 1010 Diffuse Gliomas. Acta Neuropathologica, 118, 469-474. https://doi.org/10.1007/s00401-009-0561-9
|
[14]
|
Mathur, R., Zhang, Y., Grimmer, M.R., Hong, C., Zhang, M., et al. (2020) MGMT Promoter Methylation Level in Newly Diagnosed Low-Grade Glioma Is a Predictor of Hypermutation at Recurrence. Neuro-Oncology, 22, 1580-1590. https://doi.org/10.1093/neuonc/noaa059
|
[15]
|
Cabrini, G., Fabbri, E., Lo Nigro, C., Dechecchi, M.C. and Gambari, R. (2015) Regulation of Expression of O6-Methylguanine-DNA Methyltransferase and the Treatment of Glioblastoma (Review). International Journal of Oncology, 47, 417-428. https://doi.org/10.3892/ijo.2015.3026
|
[16]
|
Van Thuijl, H.F., Mazor, T., Johnson, B.E., Fouse, S.D., Aihara, K., et al. (2015) Evolution of DNA Repair Defects during Malignant Progression of Low-Grade Gliomas after Temozolomide Treatment. Acta Neuropathologica, 129, 597-607. https://doi.org/10.1007/s00401-015-1403-6
|
[17]
|
Johnson, B.E., Mazor, T., Hong, C., Barnes, M., Aihara, K., et al. (2014) Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma. Science, 343, 189-193. https://doi.org/10.1126/science.1239947
|
[18]
|
Liau, L.M., Ashkan, K., Brem, S., Campian, J.L., Trusheim, J.E., et al. (2023) Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination with Extension of Survival among Patients with Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial. JAMA Oncology, 9, 112-121. https://doi.org/10.1001/jamaoncol.2022.5370
|
[19]
|
Buehler, M., Yi, X., Ge, W., Blattmann, P., Rushing, E., et al. (2023) Quantitative Proteomic Landscapes of Primary and Recurrent Glioblastoma Reveal a Protumorigeneic Role for FBXO2-Dependent Glioma-Microenvironment Interactions. Neuro-Oncology, 25, 290-302. https://doi.org/10.1093/neuonc/noac169
|
[20]
|
Abdelfattah, N., Kumar, P. and Wang, C. (2022) Single-Cell Analysis of Human Glioma and Immune Cells Identifies S100A4 as an Immunotherapy Target. Nature Communications, 13, Article No. 767. https://doi.org/10.1038/s41467-022-28372-y
|
[21]
|
Suvà, M.L., Rheinbay, E., Gillespie, S.M., Patel, A.P., Wakimoto, H., et al. (2014) Reconstructing and Reprogramming the Tumor-Propagating Potential of Glioblastoma Stem-Like Cells. Cell, 157, 580-594. https://doi.org/10.1016/j.cell.2014.02.030
|
[22]
|
Ahmadipour, Y., Gembruch, O., Pierscianek, D., Sure, U. and Jabbarli, R. (2020) Does the Expression of Glial Fibrillary Acid Protein (GFAP) Stain in Glioblastoma Tissue Have a Prognostic Impact on Survival? Neurochirurgie, 66, 150-154. https://doi.org/10.1016/j.neuchi.2019.12.012
|
[23]
|
Jung, C.S., Foerch, C., Schänzer, A., Heck, A., Plate, K.H., et al. (2007) Serum GFAP Is a Diagnostic Marker for Glioblastoma Multiforme. Brain, 130, 3336-3341. https://doi.org/10.1093/brain/awm263
|
[24]
|
Yang, M., Wang, B., Yin, Y., Ma, X., Tang, L., et al. (2023) PTN-PTPRZ1 Signaling Axis Blocking Mediates Tumor Microenvironment Remodeling for Enhanced Glioblastoma Treatment. Journal of Controlled Release, 353, 63-76. https://doi.org/10.1016/j.jconrel.2022.11.025
|
[25]
|
Zhao, G., Ding, L., Yu, H., Wang, W., Wang, H., et al. (2022) M2-Like Tumor-Associated Macrophages Transmit Exosomal MiR-27b-3p and Maintain Glioblastoma Stem-Like Cell Properties. Cell Death Discovery, 8, Article No. 350. https://doi.org/10.1038/s41420-022-01081-7
|
[26]
|
You, J., Tao, B., Peng, L., Peng, T., He, H., et al. (2023) Transcription Factor YY1 Mediates Self-Renewal of Glioblastoma Stem Cells through Regulation of the SENP1/METTL3/MYC Axis. Cancer Gene Therapy, 30, 683-693. https://doi.org/10.1038/s41417-022-00580-0
|
[27]
|
Gu, J., Mu, N., Jia, B., Guo, Q., Pan, L., et al. (2022) Targeting Radiation-Tolerant Persister Cells as a Strategy for Inhibiting Radioresistance and Recurrence in Glioblastoma. Neuro-Oncology, 24, 1056-1070. https://doi.org/10.1093/neuonc/noab288
|
[28]
|
Fuentes-Fayos, A.C., Vázquez-Borrego, M.C., Jiménez-Vacas, J.M., Bejarano, L., Pedraza-Arévalo, S., et al. (2020) Splicing Machinery Dysregulation Drives Glioblastoma Development/Aggressiveness: Oncogenic Role of SRSF3. Brain, 143, 3273-3293. https://doi.org/10.1093/brain/awaa273
|
[29]
|
Chonan, Y., Taki, S., Sampetrean, O., Saya, H. and Sudo, R. (2017) Endothelium-Induced Three-Dimensional Invasion of Heterogeneous Glioma Initiating Cells in a Microfluidic Coculture Platform. Integrative Biology (Camb), 9, 762-773. https://doi.org/10.1039/C7IB00091J
|
[30]
|
Schulze, M., Hutterer, M., Sabo, A., Hoja, S., Lorenz, J., et al. (2018) Chronophin Regulates Active Vitamin B6 Levels and Transcriptomic Features of Glioblastoma Cell Lines Cultured Under Non-Adherent, Serum-Free Conditions. BMC Cancer, 18, Article No. 524. https://doi.org/10.1186/s12885-018-4440-4
|
[31]
|
Kagawa, Y., Umaru, B., Kanamori, M., Zama, R., Shil, S., et al. (2022) Nuclear FABP7 Regulates Cell Proliferation of Wild-Type IDH1 Glioma through Caveolae Formation. Molecular Oncology, 16, 289-306. https://doi.org/10.1002/1878-0261.13130
|
[32]
|
Saadeh, F.S., Mahfouz, R. and Assi, H.I. (2018) EGFR as a Clinical Marker in Glioblastomas and Other Gliomas. The International Journal of Biological Markers, 33, 22-32. https://doi.org/10.5301/ijbm.5000301
|
[33]
|
Ribeiro De Souza, A.L., Marra, K., Gunn, J., Samkoe, K.S., Hull, S., et al. (2018) Optimizing Glioma Detection Using an EGFR-Targeted Fluorescent Affibody. Photochemistry and Photobiology, 94, 1167-1171. https://doi.org/10.1111/php.13003
|
[34]
|
Lassman, A.B., Roberts-Rapp, L., Sokolova, I., Song, M., Pestova, E., et al. (2019) Comparison of Biomarker Assays for EGFR: Implications for Precision Medicine in Patients with Glioblastoma. Clinical Cancer Research, 25, 3259-3265. https://doi.org/10.1158/1078-0432.CCR-18-3034
|